Department of Neurology, Hannover Medical School, Hannover, Germany.
J Neural Transm (Vienna). 2010 Mar;117(3):317-9. doi: 10.1007/s00702-010-0372-0. Epub 2010 Feb 9.
Recently, Xeomin, a novel botulinum toxin (BT) type A drug became available. Separation of complexing proteins reduced the size of its BT component, thus potentially affecting its tissue diffusion, adverse effect profile and therapeutic properties. We report the first use of Xeomin in an autonomic indication. A total of 46 patients (34 females, 12 males, age 32.7 +/- 13.2 years, disease duration 14.2 +/- 12.0 years) with symmetric bilateral idiopathic axillar hyperhidrosis and a previously stable Botox treatment received 50 MU of BT in 5 ml of 0.9% NaCl/H(2)0 in each axilla. The patient, the injector and the observer were unaware of which axilla received Xeomin and which Botox. The therapeutic effect as measured from the BT application to the onset of its decrease lasted 3.2 +/- 1.4 months and was excellent in 89% and good in 11% of the patients. Side-to-side differences of the therapeutic effect (onset latency, extent, duration) were neither detectable by the patient nor by the physician. Injection site pain was identical and adverse effects did not occur. Xeomin can be used safely and effectively for the treatment of axillar hyperhidrosis. Size differences between Xeomin and Botox do not affect their therapeutic efficacy, tissue diffusion and adverse effect profile. Identical potency labelling allows easy exchange between both products.
最近，一种新型肉毒毒素（BT）A 型药物 Xeomin 问世。复杂蛋白的分离缩小了其 BT 成分的大小，从而可能影响其组织扩散、不良影响谱和治疗特性。我们报告了 Xeomin 在自主适应证中的首次使用。共有 46 例（34 名女性，12 名男性，年龄 32.7 +/- 13.2 岁，病程 14.2 +/- 12.0 年）双侧特发性腋窝多汗症患者，且先前的 Botox 治疗稳定，在每个腋窝中接受 50 MU 的 BT，共 5 毫升 0.9%NaCl/H(2)0。患者、注射者和观察者均不知道哪个腋窝接受了 Xeomin，哪个腋窝接受了 Botox。从 BT 应用到其减少开始的治疗效果持续 3.2 +/- 1.4 个月，89%的患者效果极好，11%的患者效果良好。患者和医生均未检测到治疗效果（发病潜伏期、程度、持续时间）的双侧差异。注射部位疼痛相同，且无不良反应发生。Xeomin 可安全有效地用于治疗腋窝多汗症。Xeomin 和 Botox 之间的大小差异不会影响它们的治疗效果、组织扩散和不良影响谱。相同的效价标签允许两种产品之间轻松交换。
